tbuckley/cabot-search huggingface dataset:
SP0186 Glucocorticoid-Induced Osteoporosis
Authors: F. Buttgereit
Journal: Annals of the Rheumatic Diseases (2016)

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. In this regard, cardiovascular, gastro-intestinal, dermatological, ophthalmological, and metabolic adverse effects, the increased risk of infection, the incidence of a Cushingoid phenotype, and in particular glucocorticoid-induced osteoporosis (GIOP) are to be mentioned. However, the available data describing frequency and severity of these adverse effects are fragmentary. For example, it is difficult to distinguish specific adverse effects of a glucocorticoid therapy from other causations (e. g., the treated disease itself, other concomitant diseases or concomitant therapies). This statement is especially true for GIOP in the context of chronic inflammatory rheumatic diseases, since GIOP is counted among the two most important adverse effects of glucocorticoid therapy, by both rheumatologists and patients. This top (negative) ranking of GIOP stands in sharp contrast to the state of knowledge and scientific data, being sparse, partly conflicting and often derived from over-aged projects or studies. With regard to the pathophysiology of GIOP it seems clear, however, that glucocorticoids contribute to early and rapid bone loss and increased fracture risk which is mediated by direct effects on osteoblasts (decreased bone formation), osteoclasts (increased bone resorption) and osteocytes (increased apoptosis and sclerostin levels), and indirect effects through alterations in gonadal hormones and the neuromuscular system (Rizzoli &amp; Biver, Nat Rev Rheum, 2015). With regard to the management of GIOP, general preventive measures comprise using the lowest possible GC dose, good nutrition with sufficient intake of calcium, vitamin D, regular weight-bearing exercise, the avoidance of tobacco use and alcohol abuse and other recommendations. The treatment of GIOP consists of an early introduction of anti-osteoporotic therapy for patients receiving glucocorticoid therapy who are at increased risk of fracture. This treatment should be continued as long as the glucocorticoid dose is above intervention thresholds or fracture risk is increased. (Rizzoli &amp; Biver, Nat Rev Rheum, 2015). <h3>Disclosure of Interest</h3> F. Buttgereit Grant/research support from: Horizon Pharma, Consultant for: Horizon Pharma, Mundipharma, Pfizer, Speakers bureau: Horizon Pharma, Mundipharma, Pfizer
A Retrospective 20-Year Survey of the Incidence of Chronic Myeloid Leukemia in the Northern France Region.
Authors: Selim Corm, Ariane Leroyer, Mathieu Wemeau, Bruno Bregman, Abderrahim Oukessou, Claude Preudhomme, Jean-Pierre Jouet, Jean-Luc Lai, Thierry Facon
Journal: Blood (2006)
PTH-157 The Introduction of Biosimilar Infliximab (CT-P13) through A Managed Switching Programme Generates Significant Cost Savings with High Levels of Patient Satisfaction
Authors: S Rahmany, S Cotton, S Garnish, L McCabe, M Brown, R Saich, D Lloyd, JN Gordon
Journal: Gut (2016)

<h3>Introduction</h3> Biosimilar infliximab (CT-P5013) has been licensed in the UK for over a year with the potential for significant cost savings, though uptake to-date has been surprisingly slow. We report the introduction of biosimilar infliximab through a closely managed switching programme. <h3>Methods</h3> Following the licensing of biosimilar infliximab we made a decision to instigate a closely managed switching programme encompassing all patients on maintenance treatment with Remicade and all new starters. A working party was set up with strong managerial support to deliver the project. We initially estimated savings of £400,000/year to the local health economy. Following meetings with the 3 local CCGs agreement was confirmed for a 50:50 gain share agreement between the CCGs and the Trust. To facilitate and monitor the switching programme a new Band 7 IBD Biological nurse, a Band 7 IBD Biological pharmacist, and an IBD administrator were recruited. All patients were informed by letter of the planned switch and the rationale for it. A variety of clinical and biological markers were also recorded at each visit along with PROM data. <h3>Results</h3> To date since the start of the project on 16<sup>th</sup> September 2015 88 patients have been treated with biosimilar infliximab. 78 (63 CD/15 UC) patients on maintenance treatment with Remicade were switched to CT-P13 with unchanged efficacy and safety (the detailed results are the basis of a separate abstract); a further 10 patients received induction therapy (7 CD/3 UC). 3/88 patients requested further clarification from the IBD team with all patients subsequently agreeing to the switch. All patients were seen by either the IBD pharmacist or IBD specialist nurse and stated they felt well informed. Over the first six months the programme has generated total cost savings of £232,576.52 with projected year savings of £540,000. Staff costs totalled £90,000. PROM data from the cohort revealed very high satisfaction with treatment with a mean score of 7.3 (Range 3–10) for overall disease control. Patient feedback was universally positive. <h3>Conclusion</h3> The introduction of biosimilar infliximab can be achieved through a closely managed programme with very significant cost savings to the local health economy. Engaged conversations between primary and secondary care facilitate realising these savings allowing investment in the local IBD service with direct impact on patient care. Patients were overwhelmingly supportive of the project. Wider uptake in the UK would result in considerable cost savings to the NHS. <h3>Disclosure of Interest</h3> None Declared
Effect of CD20 Expression Levels On B-Cell Lymphoma Patients' Background and Prognosis.
Authors: Yuhko Suzuki, Tsutomu Yoshida, Naoya Nakamura, Tomiteru Togano, Koji Miyazaki, Ryuuji Ishii, Manabu Ohsaka, Mikio Danbara, Ryouichi Horie, Meijin Nakayama, Isao Okayasu, Masaaki Higashihara
Journal: Blood (2009)
Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts
Authors: Michael Y. Choi, George F. Widhopf, Januario Castro, Hongying Li, Reilly L Kidwell, Sam C Zhang, Tiffany Juarez, Susette Gorak, Laura Z. Rassenti, Karen Messer, Charles Prussak, Catriona HM Jamieson, Thomas J. Kipps
Journal: Blood (2015)
Five minutes with . . . Matthew Pennycook
Authors: Tom Moberly
Journal: BMJ (2016)

The Labour MP for Greenwich and Woolwich on why the UK needs a new clean air act

“Air pollution is a public health crisis, and it deserves a commensurate response from the government. Our response as a country to date has been lacklustre. Our collective failure is most evident in the breach of legal air pollution limits. But it’s no less manifest in the obstructive approach …
Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
Authors: Nuria Martinez-Cibrian, Teresa Garrido, Arturo Pereira, Mauricio Sarmiento, Jose Antonio Pérez-Simón, Rocio Parody, Estefania Perez, Oriana Lopez, Carlos Solano, Jose Luis Piñana, Montserrat Rovira, Francesc Fernandez-Avilés, Maria Suarez-Lledo, Alvaro Urbano-Ispizua, Carmen Martinez
Journal: Blood (2015)
Genome of the Asian longhorned beetle (Anoplophora glabripennis), a globally significant invasive species, reveals key functional and evolutionary innovations at the beetle–plant interface
Authors: Duane D. McKenna, Erin D. Scully, Yannick Pauchet, Kelli Hoover, Roy Kirsch, Scott M. Geib, Robert F. Mitchell, Robert M. Waterhouse, Seung-Joon Ahn, Deanna Arsala, Joshua B. Benoit, Heath Blackmon, Tiffany Bledsoe, Julia H. Bowsher, André Busch, Bernarda Calla, Hsu Chao, Anna K. Childers, Christopher Childers, Dave J. Clarke, Lorna Cohen, Jeffery P. Demuth, Huyen Dinh, HarshaVardhan Doddapaneni, Amanda Dolan, Jian J. Duan, Shannon Dugan, Markus Friedrich, Karl M. Glastad, Michael A. D. Goodisman, Stephanie Haddad, Yi Han, Daniel S. T. Hughes, Panagiotis Ioannidis, J. Spencer Johnston, Jeffery W. Jones, Leslie A. Kuhn, David R. Lance, Chien-Yueh Lee, Sandra L. Lee, Han Lin, Jeremy A. Lynch, Armin P. Moczek, Shwetha C. Murali, Donna M. Muzny, David R. Nelson, Subba R. Palli, Kristen A. Panfilio, Dan Pers, Monica F. Poelchau, Honghu Quan, Jiaxin Qu, Ann M. Ray, Joseph P. Rinehart, Hugh M. Robertson, Richard Roehrdanz, Andrew J. Rosendale, Seunggwan Shin, Christian Silva, Alex S. Torson, Iris M. Vargas Jentzsch, John H. Werren, Kim C. Worley, George Yocum, Evgeny M. Zdobnov, Richard A. Gibbs, Stephen Richards
Journal: Genome biology (2016)

Relatively little is known about the genomic basis and evolution of wood-feeding in beetles. We undertook genome sequencing and annotation, gene expression assays, studies of plant cell wall degrading enzymes, and other functional and comparative studies of the Asian longhorned beetle, Anoplophora glabripennis, a globally significant invasive species capable of inflicting severe feeding damage on many important tree species. Complementary studies of genes encoding enzymes involved in digestion of woody plant tissues or detoxification of plant allelochemicals were undertaken with the genomes of 14 additional insects, including the newly sequenced emerald ash borer and bull-headed dung beetle. The Asian longhorned beetle genome encodes a uniquely diverse arsenal of enzymes that can degrade the main polysaccharide networks in plant cell walls, detoxify plant allelochemicals, and otherwise facilitate feeding on woody plants. It has the metabolic plasticity needed to feed on diverse plant species, contributing to its highly invasive nature. Large expansions of chemosensory genes involved in the reception of pheromones and plant kairomones are consistent with the complexity of chemical cues it uses to find host plants and mates. Amplification and functional divergence of genes associated with specialized feeding on plants, including genes originally obtained via horizontal gene transfer from fungi and bacteria, contributed to the addition, expansion, and enhancement of the metabolic repertoire of the Asian longhorned beetle, certain other phytophagous beetles, and to a lesser degree, other phytophagous insects. Our results thus begin to establish a genomic basis for the evolutionary success of beetles on plants.
Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.
Authors: Richard H. Van der Jagt, Philip Cohen, Bruce D. Cheson, Anil Tulpule, Jordan A. Herst, Bernard Lemieux, Lee S. Schwartzberg, Katherine Sue Robinson, Jennifer W. Oliver, Michael E. Williams
Journal: Blood (2006)
Long-term Protective Changes in Adipose Tissue After Gastric Bypass
Authors: Johan Hoffstedt, Daniel P. Andersson, Daniel Eriksson Hogling, Jakob Theorell, Erik Näslund, Anders Thorell, Anna Ehrlund, Mikael Rydén, Peter Arner
Journal: Diabetes Care (2016)

OBJECTIVE Although long-term weight regain may occur after bariatric surgery, many patients are protected against relapse or development of type 2 diabetes. The study objective was to investigate whether this involves beneficial changes in adipose function. RESEARCH DESIGN AND METHODS Forty-nine obese women were investigated before and 2 and 5 years after Roux-en-Y gastric bypass (RYGB). At the 5-year follow-up, 30 subjects were pairwise matched for BMI and age to 30 control women. Clinical parameters and fine-needle biopsies from subcutaneous abdominal adipose tissue were obtained; fat cell size and number, lipolysis, adiponectin, and proinflammatory protein secretion were determined. RESULTS After 2 years, BMI decreased from 43 to 29 kg/m2, which was accompanied by improvements in insulin sensitivity (HOMA of insulin resistance [HOMA-IR]), increased circulating and adipose secreted adiponectin, and decreased adipose lipolysis and fat cell size but no change in adipocyte number. Between 2 and 5 years after surgery, BMI had increased to 31 kg/m2. This was associated with slightly increased HOMA-IR and unaltered circulating or adipose secreted adiponectin but higher secretion of tumor necrosis factor-α and increased lipolysis and number of fat cells but no change in adipocyte size. All these parameters, except lipolysis, were significantly more favorable compared with those in matched control subjects. Furthermore, the relationship between HOMA-IR and circulating adiponectin was less steep than in control subjects. CONCLUSIONS RYGB improves long-term insulin sensitivity and adipose phenotypes beyond the control state despite weight regain. Postoperative beneficial alterations in adipose function may be involved in the diabetes-protective effect of bariatric surgery.
Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine
Authors: Jie Li, Aiyuan Guo, Wangqing Chen, Lianghua Bin, Yijing He, Wu Zhu, Cong Peng, Siyu Yan, Mingliang Chen, Jianglin Zhang, Juan Su, Mei Yi, Zhaoqian Liu, Wei Zhang, Weiqi Zeng, Donald Y.M. Leung, Xiang Chen
Journal: Journal of Allergy and Clinical Immunology (2016)
SAT0288 Clinical Phenotyping in 608 Patients from The United Kingdom Primary Sjögren's Syndrome Registry
Authors: N. Howard Tripp, D. Lendrem, J. Tarn, K. Hackett, W.-F. Ng
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Primary Sjögren9s Syndrome (pSS) is a chronic multi-system disease causing a wide-range of symptoms including dryness, pain and fatigue.<sup>1,2</sup> Individual experiences of pSS differ considerably resulting in a heterogeneous patient population.<sup>3</sup> These differences in disease-manifestation have not yet been characterised and the biological basis of varied patient-reported outcomes remains unclear. <h3>Objectives</h3> We aim to identify distinct clinical phenotypes within pSS, using patient-reported symptoms and to determine whether such clinical subgroups display differences in healthy utility values, and biological measures of disease activity. <h3>Methods</h3> Symptoms of 608 patients on the United Kingdom Primary Sjögren9s Syndrome Registry (UKPSSR) were reviewed.<sup>4</sup> Phenotypes were identified using hierarchical cluster analysis of patient reported rating scales for pain, fatigue, dryness, anxiety and depression symptoms. Non-parametric analysis of variance was used to evaluate differences between clusters. <h3>Results</h3> Four phenotypic clusters were identified: High symptom burden (HSB), Low symptom burden (LSB), dryness dominant (DD) and Low Anxiety and Depression (LAD). Not surprisingly, there were significant differences between these groups in measures of health status and quality of life (EQ-5D p&lt;0.0001, TTO &lt;0.0001). More interestingly, objective measures of disease activity (ESSDAI p=0.039), objective dryness (salivary flow p=0.007, Schirmer9s p=0.014), and biological parameters (IgG p&lt;0.0001, lymphocytes p=0.0005, ESR p=0.003) suggest these subgroups may reflect different underlying endotypes. <h3>Conclusions</h3> Distinct biological differences may underlie pSS clinical phenotypes. The identification of these different clinical subsets of pSS could impact on the future study and management of the condition using a stratified approach. <h3>References</h3> R. I. Fox, Sjogren9s syndrome. Lancet 366,321–331 (2005) W. F. Ng, S. J. Bowman, Primary Sjogren9s syndrome: too dry and too tired. Rheumatology 49, 844–853 (2010) L. Robinson, K. Hackett, S.J. Bowman, B. Griffiths, W.F. Ng, P. Gallagher, Understanding the gap between subjective symptoms and objective illness markers in Primary Sjogren9s Syndrome. Annals of the Rheumatic Diseases 73, 188–189 (2014). W. F. Ng, S. J. Bowman, B. Griffiths, UK Sjogren9s Syndrome Group, United Kingdom Primary Sjogren9s Syndrome Registry-a united effort to tackle an orphan rheumatic disease. Rheumatology 50, 32–39 (2011) <h3>Acknowledgement</h3> We would like to thank all the patients and healthy volunteers who have participated in the UKPSSR. This study received grant support from the Medical Research Council, British Sjögren9s Syndrome Association and the Newcastle University. <h3>Disclosure of Interest</h3> None declared
Analysis of the Tissue-Specific Expression Requirements and Identification of Cooperating Mutations for Leukemogenesis in an Inducible CALM/AF10 Knock-in Mouse Model
Authors: Sayantanee Dutta, Alexandre Krause, Sebastian Vosberg, Tobias Herold, Bianca Ksienzyk, Leticia Quintanilla-Fend, Belay Tizazu, Alexander Graf, Stefan Krebs, Helmut Blum, Philipp A Greif, Marlon Schneider, Maik Dahlhof, Karsten Spiekermann, Ursula Zimber-Strobl, Eckhard Wolf, Stefan K Bohlander
Journal: Blood (2014)
Rac GTPase Survival Signaling Through Anti-Apoptotic Bcl-2 Proteins Reveals a Target for Combination Therapy in MLL-AF9 Acute Myeloid Leukemia
Authors: Benjamin Mizukawa, Mahesh Shrestha, Mark Wunderlich, Fu-Sheng Chou, Andrea Griesinger, Ashish Kumar, Yi Zheng, David A. Williams, James C. Mulloy
Journal: Blood (2011)
TNF-alpha mediated up-regulation of the multidrug resistance gene mdr1b but not of mrp1 in rat hepatocytes is dependent on NF-kappa B activation
Authors: J.E. Ros, M Geuken, JD Schuetz, F Kuipers, MP Manns, H Moshage, PL Jansen, C Trautwein, M Muller
Journal: Hepatology (1999)
Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).
Authors: Kirsten Fischer, Paula Cramer, Stephan Stilgenbauer, Raymonde Busch, Leopold Balleisen, Julia Kilp, Anna-Maria Fink, Sebastian Boettcher, Matthias Ritgen, Michael Kneba, Peter Staib, Hartmut Döhner, Silke Schulte, Barbara F. Eichhorst, Michael Hallek, Clemens-Martin Wendtner
Journal: Blood (2009)
Back to basics with some new tools: first ensure the safety of sporting environments
Authors: Caroline F Finch, James C Brown, Clint Readhead, Mike Lambert, Wayne Viljoen
Journal: British Journal of Sports Medicine (2016)

Recently, effort has been put into the development of sports injury prevention programmes and accompanying education training for specific sports, such as BokSmart (Rugby Union, http://boksmart.co.za/content/what-is-boksmart), FootyFirst (Australian football, http://www.aflcommunityclub.com.au/index.php?id=906) and FIFA 11+ (Soccer, http://f-marc.com/11plus/11plus/). Many involve targeted exercise interventions for players to undertake via coach instructions. It is assumed that the physical environments for this are safe, but this aspect is rarely discussed in the literature.

Before any form of sporting activity, the playing environment needs to be hazard-free and suitable for the intended activity. This applies to both fitness facilities1 and outdoor sporting fields.2 The standard and condition of the playing surfaces themselves are critical for sports safety, and this requires maintaining turf surfaces and checking the safety of sports environments before play. Identifying, removing and controlling hazards are crucial for reducing sports-injury risk.1 ,2 In professional and high-level sport, this process is routinely undertaken by the officials and sport management staff, especially those linked with specific sports facilities who are present on the days of activity.3 In community club sport, this …
Cardiac Phenotype and Long-Term Follow-Up of Patients With Mutations in NKX2-5 Gene
Authors: Philippe Maury, Estelle Gandjbakhch, Alban-Elouen Baruteau, Francis Bessière, Florence Kyndt, Patrice Bouvagnet, Anne Rollin, Damien Bonnet, Vincent Probst, Alice Maltret
Journal: Journal of the American College of Cardiology (2016)
SP0159 Ethical Implications of Employing e-Health Solutions To Promote Healthy Lifestyles
Authors: M. Niezen
Journal: Annals of the Rheumatic Diseases (2016)

Increasingly e-health solutions and specifically eHealth applications (health apps) combine interactive persuasive technologies [1,2] with behaviour change systems [3]. Within the field of mobile health (mHealth) these technologies can be used for influencing human behaviour and empowering users to gain or maintain a healthy lifestyle. However, such health apps are relatively new emerging technologies and also come with expectations and worries with respect to their unknown and unintended effects and related ethical issues that might arise from their design or distribution. In this presentation I will discuss how health apps can raise issues on matters such as privacy, autonomy, liability and division of responsibilities among stakeholders. In addition, I will discuss potential ways of developing e-Health applications in a more responsible manner, taking into account ethical, legal and social preconditions for e-Health9s acceptance. <h3>References</h3> B. Fogg, Persuasive Technology: Using Computers to Change What We Think and Do (Interactive Technologies), 2002. B. Fogg, G. Cuellar, and D. Danielson, Motivating, influencing, and persuading users: An introduction to captology, Hum. Comput. Interact. Fundam., pp. 109–122, 2009. H. Oinas-Kukkonen and M. Harjumaa, Persuasive systems design: Key issues, process model, and system features, Commun. Assoc. Inf. Syst., vol. 24, no. 1, p. 28, 2009. <h3>Disclosure of Interest</h3> None declared
AB0966 Colour Doppler Ultrasonography Is Specific but Not Sensitive in Diagnosis of Carpal Tunnel Syndrome
Authors: O.Z. Shehata, D.M. Sharaf, M.A. Mortada, F.A. Elsayed
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Carpal tunnel syndrome (CTS) is the most common form of peripheral entrapment neuropathies. Ultrasonography (US) has been used to diagnose CTS with a good sensitivity and specificity.There is no consensus about the role of colour Doppler US in diagnosis of CTS (1). <h3>Objectives</h3> To assess the diagnostic role of color Doppler ultrasonography in idiopathic CTS. <h3>Methods</h3> This study included 2 groups. The first group included 35females middle aged (32.1±4.8) patients with idiopathic CTS. The second group included 35 healthy middle aged (40.1±7.6) females. The diagnosis of CTS was done clinically and by nerve conduction studies.Ultrasonography of the median nerve was performed to find colour Doppler signals, wrist cross sectional area, forearm cross sectional area, flattening ratio, flexor retinaculum bowing and pronator quadratus ratio by use of high frequency (5–12MHz) linear probe diagnostic ultrasound. <h3>Results</h3> There was a statistical highly significant difference between control group and patients with CTS regarding colour Doppler signal (p=0.00).the specificity of CDUS in diagnosis of CTS was excellent (100%) but its sensitivity was poor (22.9%) with an accuracy of 61.4%. As regards the other US parameters, flattening ratio was the most accurate method (86.4%) with a senstivity (88.7%) and a specificity of (83.3%).There was a statistical highly significant positive correlation between nerve conduction study grading and Color Doppler ultrasonography (p=0.005). <h3>Conclusions</h3> CDUS is a highly specific test in evaluation of idiopathic CTS. It represents a useful confirmatory tool in diagnosis. Flattening ratio is the most accurate grey scale US parameter and highly correlated with CT severity. <h3>References</h3> Akcar N, et al. (2010).Korean Journal of Radiology; 11 (6): 632–639. <h3>Disclosure of Interest</h3> None declared
Myeloproliferative Neoplasm Resembling Polycythemia Vera In a Patient with t(2;11)(p21;q23) Translocation and Persistently Elevated MiR-125b-1
Authors: Stanley R. McCormick, Craig W. S. Howe, Pierre Brousset, Anil K. Tadavarthy, Cathy Quelen, Nicole Dastugue, Lisa M. Bartholomaus, Karen J. Cunnien, Sandy R. Woker, Kathryn M. Lapp, Katie A. Peterson, Jamil Ahmad, Lara S. Pliml, Rodney R. Higgins
Journal: Blood (2010)